Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash Items
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Net Cash Flow: 2023-2025

Historic Net Cash Flow for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$2.3 million.

  • BioLineRx's Net Cash Flow fell 158.36% to -$2.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$3.0 million, marking a year-over-year decrease of 696.58%. This contributed to the annual value of $6.2 million for FY2024, which is 200.83% up from last year.
  • Latest data reveals that BioLineRx reported Net Cash Flow of -$2.3 million as of Q2 2025, which was down 72.91% from -$1.3 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Net Cash Flow peaked at $3.9 million during Q2 2024, and registered a low of -$3.7 million during Q4 2023.
  • Its 3-year average for Net Cash Flow is -$354,600, with a median of -$1.1 million in 2024.
  • As far as peak fluctuations go, BioLineRx's Net Cash Flow skyrocketed by 218.34% in 2024, and later tumbled by 178.27% in 2025.
  • Over the past 3 years, BioLineRx's Net Cash Flow (Quarterly) stood at -$3.7 million in 2023, then soared by 139.25% to $1.4 million in 2024, then crashed by 158.36% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q2 2025, -$1.3 million for Q1 2025, and $1.4 million during Q4 2024.